By Gina Lee
Investing.com – Hong Kong’s CK Life Sciences International Holdings Inc (HK:) saw its stock jump on the back of a deal to distribute COVID-19 rapid test kits.
The company will distribute the rapid test kits manufactured by Singapore-based medical technology company Biolidics (SI:) in Hong Kong, said a Wednesday press release.
Biolidics received provisional authorization from Singapore’s Health Sciences Authority, and the test kit is already in use in Singapore.
CK Life Sciences’ Hong Kong stocks jumped 12.77% to HK$1.060 by 12:28 AM ET (5:28 AM GMT) on Thursday, while Biolidics’ Singapore stocks rose by 3.28%.
Meanwhile, parent company CK Hutchison Holdings (HK:) saw its Hong Kong stocks slide 1.44% to HK$56.28.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Be the first to comment